Guo Weiyan 1,2,3 , Lin Xuemei 1,3 , Wu Songdi 1,3
  • 1. Department of Neuro-ophthalmology, The First Affiliated Hospital of Northwest University (Xi'anNo.1 Hospital), Xi'an 710002, China;
  • 2. Department of Pharmacy, The First Affiliated Hospital of Northwest University (Xi'an No.1 Hospital), Xi'an 710002, China;
  • 3. Xi'an Key Laboratory of Innovation and Transformation of Neuroimmunological Diseases, Xi'an 710002, China;
Wu Songdi, Email: wusongdi@gmail.com
Export PDF Favorites Scan Get Citation

Immune checkpoint inhibitors (ICI) have revolutionized the field of oncology by regulating the interaction between immune cells and cancer cells and promoting the disinhibition of the immune system, thus targeting various types of malignant tumors. However, the regulation of the immune system can also trigger related adverse reactions. Currently, there are no specific clinical guidelines for the treatment of these adverse reactions. Treatment decisions largely depend on clinical judgment and experience.The pathogenesis of ICI-related ocular adverse events is not fully understood at present. Further research on the specific mechanisms of action can provide new insights into the early diagnosis and treatment of ICI-related ocular adverse events.

Citation: Guo Weiyan, Lin Xuemei, Wu Songdi. Research progress on the ocular adverse effects associated with immune checkpoint inhibitor therapy. Chinese Journal of Ocular Fundus Diseases, 2023, 39(12): 1033-1038. doi: 10.3760/cma.j.cn511434-20230313-00120 Copy

  • Previous Article

    Recent advances in suprachoroidal drug delivery for the treatment of ocular posterior segment diseases
  • Next Article

    Paying attention to importance to the innovation in retinal surgery